Alumis Inc

This study tested whether a daily pill called ESK-001 can reduce psoriasis severity in adults with moderate to severe plaque psoriasis. Over 900 participants took ESK-001, a placebo (dummy pill), or an approved psoriasis drug (apremilast) for 24 weeks. Researchers measured skin c…

This study tested a new daily pill, ESK-001, in 862 adults with moderate to severe plaque psoriasis. The goal was to see if it reduces skin symptoms like redness and scaling better than a placebo or an existing drug. Participants took the pill for 24 weeks and had regular checkup…

This study looked at how the experimental drug ESK-001 affects the heart's electrical activity in 52 healthy adults aged 18 to 55. Participants received ESK-001, a placebo, and moxifloxacin at different times to compare effects. The main goal was to see if ESK-001 causes any chan…

This study looked at how different levels of kidney function affect the way the body handles a single dose of the experimental drug ESK-001. Researchers compared healthy volunteers to people with mild, moderate, and severe kidney impairment. The goal was to understand how the dru…

This study looked at how the drug ESK001 behaves in people with different levels of liver function. 32 adults with healthy livers or mild to severe liver impairment received a single dose. The goal was to measure drug levels and check for side effects, not to treat any condition.

This early-stage study tested the safety and tolerability of a new drug called A-005 in 135 healthy adults aged 19 to 55. Participants received either single or multiple doses of the drug or a placebo. The goal was to check for side effects and how the drug moves through the body…